David Crean | MediciNova

Navigating the financial life cycle of a life sciences company requires a delicate balance between understanding complex clinical data and executing high-level corporate finance strategies.

In this live broadcast from Day 3 of BIO 2026 in San Diego, we sit down with David Crean, an industry executive at MediciNova. Bringing a highly diverse professional background that spans a PhD in physics, pre-med training, an MBA in finance, and a history in minor league baseball, David provides a comprehensive, multi-dimensional perspective on the current state of biopharma investment.

David joins us to pull back the curtain on current public and private markets, highlighting where venture capital is bottlenecked and where commercial deal-making is exploding.